Go Pro
NYSEAMERICAN:NSRX

Nasus Pharma Q2 2026 Earnings Report

Nasus Pharma logo
$3.73 -0.02 (-0.53%)
As of 09/4/2026 04:10 PM Eastern

Nasus Pharma EPS Results

Actual EPS
-$0.27
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nasus Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nasus Pharma Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nasus Pharma Earnings Headlines

Nasus Pharma Boosts Cash and Equity in First-Half 2026 Filing
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Nasus Pharma CFO Eyal Rubin to leave
See More Nasus Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nasus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nasus Pharma and other key companies, straight to your email.

About Nasus Pharma

Nasus Pharma (NYSEAMERICAN:NSRX) is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.

View Nasus Pharma Profile